Evaluation of Pharmacokinetics, Safety, And Tolerability Of Ertugliflozin (PF-04971729, MK-8835) In Japanese And Western Healthy Participants (MK-8835-041)

NCT01223339 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

24

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG: Ertugliflozin
DRUG: Placebo
DRUG: Ertugliflozin
DRUG: Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

[object Object]